Brought to you by:
Study links clopidogrel genetic variants to cardiovascular risk after PAD intervention
Genetic variants that reduce the effectiveness of clopidogrel may increase the risk of heart attack and stroke in patients undergoing peripheral artery disease (PAD) interventions, according to research presented at VAM 2026. The study found that around one in five…
Trial supports full-dose anticoagulation to prevent blood clots in COVID-19 patients
Treatment of critically ill COVID-19 patients with full-dose anticoagulation lowers the risk of venous and arterial clotting complications by 44% compared with the standard dose, according to late breaking research presented in a Hot Line session at ESC Congress 2022 (Aug. 26–29) in Barcelona, Spain.…
Clopidogrel exposure along with aspirin and rivaroxaban should be ‘minimized or avoided’ in PAD revascularization
“More bleeding with background clopidogrel, even if not severe by adjudication, may be associated with broad consequences, including discontinuation of therapies. In the absence of clear benefit, clopidogrel exposure along with aspirin and rivaroxaban should be minimized or avoided to…